[{"PropertyPlantAndEquipmentNet_0_Q3_USD":3342000.0,"IndefiniteLivedIntangibleAssetsExcludingGoodwill_0_Q3_USD":27200000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":14247000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":5821000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":41582000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":45453000.0,"AccountsAndOtherReceivablesNetCurrent_0_Q3_USD":197000.0,"InterestAndOtherIncome_3_Q3_USD":313000.0,"InterestAndOtherIncome_1_Q3_USD":145000.0,"CommitmentsAndContingencies_0_Q3_USD":null,"GainLossOnSaleOfPropertyPlantEquipment_3_Q3_USD":23000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":10253000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3_Q3_pure":0.98,"BusinessCombinationContingentConsiderationLiability_0_Q3_USD":7107000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":2548000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3_Q3_pure":0.013,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1_Q3_pure":0.012,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-197212000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":63000.0,"AssetsCurrent_0_Q3_USD":426555000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3_Q3_USD":0.0,"ContractWithCustomerLiability_0_Q3_USD":601000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":4129626.0,"CommonStockSharesIssued_0_Q3_shares":46663340.0,"Assets_0_Q3_USD":460201000.0,"ShareBasedCompensation_3_Q3_USD":5813000.0,"MarketableSecuritiesCurrent_0_Q3_USD":350905000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"DeferredTaxLiabilities_0_Q3_USD":1613000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-44000.0,"InvestmentsAndCash_0_Q3_USD":423100000.0,"OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_0_Q3_USD":0.0,"ProceedsFromStockPlans_3_Q3_USD":2053000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q3_pure":0.98,"IncomeTaxExpenseBenefit_3_Q3_USD":-227000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":-227000.0,"CommonStockValue_0_Q3_USD":47000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3_Q3_USD":1757000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":2291000.0,"ContractWithCustomerAssetNet_0_Q3_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":271946000.0,"ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3_Q3_USD":3500000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":3016000.0,"ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1_Q3_USD":3500000.0,"CostsAndExpenses_1_Q3_USD":20977000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":129000000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_3_Q3_USD":-50363000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q3_USD":-20452000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-50404000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-20496000.0,"OtherAssetsNoncurrent_0_Q3_USD":98000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":72184000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":1713000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":1557576000.0,"Liabilities_0_Q3_USD":23489000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":-41000.0,"CostsAndExpenses_3_Q3_USD":55220000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":13557000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.01,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"IncreaseDecreaseInOtherOperatingLiabilities_3_Q3_USD":-3855000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-1123459000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":28348000.0,"CommonStockSharesOutstanding_0_Q3_shares":46663340.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":325342000.0,"ConstructionInProgressExpendituresIncurredButNotYetPaid_3_Q3_USD":46000.0,"ContractWithCustomerLiabilityRevenueRecognized_3_Q3_USD":3400000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q3_USD":0.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":15000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-50590000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-20679000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":3029000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-46386000.0,"LiabilitiesCurrent_0_Q3_USD":14176000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0_Q3_USD":140600000.0,"AccountsPayableCurrent_0_Q3_USD":836000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":3269000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3_Q3_pure":0.97,"IntangibleAssetsNetExcludingGoodwill_0_Q3_USD":27190000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1_Q3_pure":0.011,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3_Q3_pure":0.008,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q3_USD":2004000.0,"InterestReceivable_0_Q3_USD":800000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0_Q3_USD":47300000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_3_Q3_USD":3407000.0,"OtherLiabilities_0_Q3_USD":9321000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":350953000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":895000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3_Q3_USD":21.86,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q3_USD":41.34,"IncreaseDecreaseInAccountsAndOtherReceivables_3_Q3_USD":-1549000.0,"ProceedsFromSaleOfProductiveAssets_3_Q3_USD":25000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":2261000.0,"CommonStockSharesAuthorized_0_Q3_shares":297000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":4317000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":153000.0,"OperatingIncomeLoss_3_Q3_USD":-50903000.0,"OperatingIncomeLoss_1_Q3_USD":-20824000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3_Q3_pure":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q3_pure":0.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":269893000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_3_Q3_USD":1160000.0,"PreferredStockValue_0_Q3_USD":null,"LiabilitiesAndStockholdersEquity_0_Q3_USD":460201000.0,"PreferredStockSharesAuthorized_0_Q3_shares":3000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":5813000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":3029000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q3_USD":33700000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":1366000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-1.21,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.45,"OtherLiabilitiesNoncurrent_0_Q3_USD":7600000.0,"OtherLiabilitiesCurrent_0_Q3_USD":1721000.0,"StockholdersEquity_0_Q3_USD":436712000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_1_Q3_USD":1901000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":38633000.0,"Ticker":"CLDX","CIK":"744218","name":"CELLDEX THERAPEUTICS, INC.","OfficialName":"Celldex Therapeutics Inc.","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1601609341.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20211109"}]